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Background: To evaluate the effect of pretreatment with the mixed alpha- and beta-adrenergic blocker,
labetalol, on blood pressure instability during surgical resection of pheochromocytoma.
Methods: Blood pressure stability and surgical results were compared between patients in the saline (n = 11)
and labetalol (n = 15) groups. Anesthesia was induced with fentanyl, sodium thiopental and atracurium, and
maintained with isoflurane in a 50% oxygen/nitrous oxide mixture. Intravenous labetalol was administered
in the labetalol group before surgical incision, with the maximal dose being 1.2 mg/kg, while normal saline
was administered to patients in the control, saline, group. Supplemental intravenous sodium nitroprusside
(SNP) infusion was administered whenever systolic blood pressure exceeded 180 mmHg. The number of
patients with intraoperative hypertension or hypotension, dosage of SNP administered, number of
intraoperative hypertension episodes, use of fluid and blood transfusion, and heart rate (defined as the mean
of heart rate every 5 minutes throughout the operation) were compared between these two groups.
Results: The number of patients with intraoperative hypertension, number of patients receiving SNP, dose of
SNP administered, and number of hypertension episodes were significantly lower in patients who received
labetalol pretreatment than in control patients.
Conclusion: This study has demonstrated that labetalol pretreatment (1.2 mg/kg) with supplemental SNP
provides more favorable blood pressure control during surgical resection of pheochromocytoma than with
SNP alone. [J Formos Med Assoc 2006;105(3):189–193]
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Pheochromocytoma is a rare catecholamine-
producing tumor derived from chromaffin tissues.
Intraoperative management of the fluctuating
blood pressure caused by catecholamine surge
during tumor resection poses a challenge to both
surgeons and anesthesiologists with the potential
for cardiovascular or cerebrovascular complica-
tions. Labetalol, an alpha- and beta-adrenergic
blocker, has been used in pheochromocytoma sur-
gery since 1976.1–3 However, the concern of po-
tential hypotensive effects after tumor resection
may have limited its extensive use. We previously
demonstrated that intravenous labetalol (2 mg/
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kg) administered as a loading dose exclusively pri-
or to tumor resection could minimize hyperten-
sive attack, but with increased risks of hypotension
after tumor resection.4 As preoperative oral anti-
hypertensive medication for hypertensive patients
is commonly given with the aim of providing a
more stable intraoperative hemodynamic condi-
tion, we hypothesized that intravenous labetalol
pretreatment could also minimize blood pressure
fluctuations and decrease the dose requirement of
short-acting vasodilators, such as sodium nitro-
prusside (SNP), during pheochromocytoma
surgery. This study evaluated the effectiveness of
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2% and 2.5% at the beginning of anesthesia, at
2.5% during tumor manipulation, and decreased
if indicated after tumor resection. Atracurium 5 mg
was given every 30 minutes and intermittently as
required.
For patients in the saline group (n = 11), nor-
mal saline was given before tumor resection while
SNP was infused intravenously and titrated to
maintain a systolic blood pressure (SBP) < 180
mmHg during tumor manipulation. In the labeta-
lol group (n = 15), a 10-mg bolus of intravenous
labetalol was administered intermittently, before
the beginning of surgical incision, to attain a max-
imal dose of 1.2 mg/kg, unless SBP fell below 90
mmHg, mean arterial blood pressure (MAP) be-
low 60 mmHg, or heart rate < 45 bpm. Blood pres-
sure lower than the above criteria or severe brady-
cardia was managed with fluid challenge, 0.5
mg of atropine and 5 mL of 5% calcium chloride.
No further labetalol was administered after the
surgical incision had begun. For this group of
patients, supplemental SNP infusion was started
and titrated only if SBP increased to > 180 mmHg
during tracheal intubation or surgical resection
of the tumor. After tumor resection, a vasopressor
(norepinephrine) was used if MAP fell below 60
mmHg. Throughout the intraoperative period,
glucose-sparing crystalloid solution was used for
fluid maintenance. Hypoglycemia was corrected
with 5% dextrose in saline. Blood transfusion was
initiated when blood loss exceeded 500 mL. CVP
was maintained between 10 and 12 cmH2O. Arte-
rial blood gas and serum electrolytes were analyzed
hourly throughout the operation and in the post-
anesthesia care unit. Blood sugar was also meas-
ured hourly for 24 hours.
Intraoperative hypertension was defined as SBP
> 180 mmHg, and intraoperative hypotension as
SBP < 90 mmHg. During surgical resection of
pheochromocytoma, the number of patients with
intraoperative hypertension or hypotension, and
those receiving SNP in the two groups were com-
pared by the chi-square test and likelihood ratio.
The dosage of SNP administered, number of intra-
operative hypertension episodes, fluid and blood
transfusion, and heart rate (defined as the mean
pretreatment with a lower dose of labetalol (1.2
mg/kg) on perioperative hypertension and hypo-
tension in patients undergoing surgical resection
of pheochromocytoma.
Methods
From June 1992 through December 2001, after
obtaining approval from our institutional clinical
trial committee and informed consent from the in-
volved patients, 26 Taiwanese patients undergo-
ing pheochromocytoma resection and with nor-
mal 48-hour inhospital blood pressure (defined
as < 165/90 mmHg) were included in this study.
Patients with orthostatic hypotension or tachyar-
rhythmia after preoperative medical treatment
were excluded. The diagnosis of pheochromocy-
toma was based on clinical signs and positive
MIBG (metaiodobenzylguanidine) scintigraphy.
Eleven consecutive patients were assigned to the
control, saline, group, and another 15 consecutive
patients to the labetalol group. Individual anti-
hypertensive agents were prescribed as routine
until the morning of surgery. Pathologic proof of
pheochromocytoma was eventually obtained in
all cases. Twelve of 26 patients (46.7%) had re-
ceived phenoxybenzamine as antihypertensive
medication, and the number of patients who re-
ceived phenoxybenzamine between the two groups
was not significantly different.
No premedication was provided. Fentanyl 100
μg and valium 5 mg were administered intrave-
nously when the patients arrived at the operating
theater. Before the induction of anesthesia, a
radial artery catheter and a pulmonary arterial
catheter were inserted under local anesthesia.
Electrocardiography, pulse oximetry and central
venous pressure (CVP) were continuously mon-
itored. Anesthesia was induced with intravenous
administration of atropine (0.3 mg), fentanyl (3–
4 μg/kg), sodium thiopental (4–5 mg/kg) and
atracurium (0.6–0.8 mg/kg). After intubation, an-
esthesia was maintained with isoflurane in a 50%
oxygen/nitrous oxide mixture (2:2 L/min). The
concentration of isoflurane was kept between
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value of heart rate every 5 minutes throughout the
operation) between these two groups were also
compared by Student’s t test and Fisher’s exact
test. A probability value of p < 0.05 was consid-
ered to be significant.
Results
The demographic and perioperative data of the
two groups are shown in the Table. Hypertensive
episodes occurred in 40% of patients in the labeta-
lol group (total 13 episodes), and 100% of patients
in the control, saline, group (total 41 episodes).
The number of patients with hypertensive episodes
and the number of hypertensive episodes in the
labetalol group were both significantly lower
than that in the saline group. The heart rate of the
patients in the labetalol group was significantly
lower than that of the saline group. The number
of patients receiving SNP in the labetalol group
(40%) was significantly lower than that in the
saline group (100%). The mean dose of SNP used
in the labetalol group (n = 6; 2.0 ± 1.6 mg) was
significantly lower than that used in the saline
group (n = 11; 6.0 ± 3.7 mg). This indicates that
labetalol pretreatment is effective in managing
intraoperative hypertension and reducing the
frequency and dose of SNP used during surgical
resection of pheochromocytoma.
Substantial blood pressure drop occurred soon
after loading in 46.7% of patients in the labetalol
group, but blood pressure was immediately re-
stored to normal after fluid challenge and use of
medications. No patient in the labetalol group
needed SNP during intubation. A vasopressor was
used only when hypotension occurred, therefore,
the need for vasopressor use after tumor resection
was taken to reflect the frequency of hypotensive
episodes after tumor resection. The need for vaso-
pressor usage for hypotension (SBP < 90 mmHg)
was not significantly different between the two
groups (labetalol group, 3/15 patients; saline
group, 4/11 patients), indicating that intravenous
labetalol given as a loading dose does not ag-
gravate the hypotension that might occur after
tumor resection. No patient in the two groups
developed hypotension within 24 hours post-
operatively.
There was massive intraoperative blood loss
due to tearing of the inferior vena cava in two pa-
tients (7500 mL and 3500 mL, respectively) in the
Table.  Patient demographic and perioperative data
Labetalol (n = 15) Saline (n = 11)
Gender (M/F) 7/8 5/7
Age (yr) 40.9 ± 13.9 44.3 ± 9.00
Weight (kg) 57.1 ± 10.8 56.2 ± 10.4
Patients with intraoperative hypertension (n) 06* 110
Total hypertensive episodes (n) 13* 410
Hypertensive episodes in patients with intraoperative hypertension (n) 0.2.2 ± 1.6* 3.7 ± 1.2
Labetalol dose administered (mg) 66.7 ± 19.7 0
Patients receiving SNP (n) 6 110
SNP dose in patients receiving SNP (mg) 02.0 ± 1.6* 6.0 ± 3.7
Range of SNP dose administered (mg) 0.8–5 2–15
Heart rate (bpm) 073.3 ± 11.2* 103.2 ± 15.50
Patients with hypotension before tumor resection (n) 07* 0
Patients with hypotension during tumor resection (n) 3 4
Patients with hypotension within 24 hr after operation (n) 0 0
Crystalloid administered (mL) 3816 ± 1203 3652 ± 1546
Blood transfused (pRBC, units) 3.7 ± 5.4 2.2 ± 1.4
*p < 0.05 vs. saline group. pRBC = packed red blood cells; SNP = sodium nitroprusside.
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labetalol group. One of these patients died the
following day due to intractable bleeding. The
volume of fluid administered and blood trans-
fused during operation was not significantly dif-
ferent between the two groups (Table). Three pa-
tients in the labetalol group and none in the saline
group developed postoperative hypoglycemia af-
ter tumor resection. No neurologic deficit or mor-
tality related to anesthesia occurred.
Discussion
This study demonstrated that 1.2 mg/kg labetalol
pretreatment reduces the incidence of hypertensive
episode and the requirement for SNP during sur-
gical resection of pheochromocytoma. More im-
portantly, we demonstrated that labetalol, at 1.2
mg/kg bolus dose, is associated with minimal
risk of postoperative hypotension as shown in a
previous study.4 Although the sample size was
small, partly due to the low incidence of pheo-
chromocytoma, and, thus, did not permit a ran-
domized approach, the effect of labetalol pretreat-
ment on suppressing hypertension during pheo-
chromocytoma surgery could still be evaluated.
Fewer patients in the labetalol group exhibited
hypertensive episodes, and patients in this group
had more stable heart rates. This indicates that
labetalol pretreatment with adjuvant SNP exerts
better control on blood pressure instability than
SNP alone in surgical resection of pheochro-
mocytoma.
There have been many reports on the manage-
ment of intraoperative hemodynamic changes
with different antihypertensive agents during phe-
ochromocytoma resection.5–10 Short acting agents
were generally considered to be superior to long-
acting ones because their antihypertensive effect
subsides sooner, which may be considered bene-
ficial, especially once the tumor has been resected.
The availability of labetalol, which has alpha- and
beta-adrenergic blocking effects, had provided an
alternative choice of antihypertensive agent dur-
ing resection of pheochromocytoma. Kaufman
first reported its use in an intermittent intravenous
bolus manner during such surgeries in 1979.11
However, due to its long half-life (3–4 hours) and
the potential for hypotensive effects after tumor
resection, labetalol use for the management of
hypertension is not common during pheochro-
mocytoma surgery, and it is generally administered
only at the initiation of anesthesia, as in our hos-
pital, to avoid the aggravation of blood pressure
drop after tumor resection, which usually occurs
2–3 hours after operation. In our previous study,
a total labetalol dose of 2 mg/kg was used, but
resulted in a notable blood pressure drop soon
after administration.4 Therefore, the total dose of
labetalol was reduced to 1.2 mg/kg in this study.
From our results, the need for vasopressor usage
after tumor resection in the labetalol group was
not significantly different from that in the saline
group, and no patients in the labetalol group had
hypotension within 24 hours postoperatively
(except for one patient who suffered from intrac-
table bleeding after tumor resection). This indi-
cated that labetalol pretreatment given only at
the initiation of anesthesia does not aggravate
the hypotension which usually occurs after tumor
resection, which is compatible with the results of
our previous study.4 Although seven patients had
obvious blood pressure drop soon after labetalol
loading, the blood pressure was soon restored
to normal after fluid challenge and the use of med-
ications such as atropine or calcium. As the dura-
tion is more crucial than the frequency of hypo-
tensive episodes, and since there were no cerebro-
vascular sequelae in the postoperative period, we
considered those episodes as being not clinically
hazardous.
Although phenoxybenzamine was given pre-
operatively in the majority of patients in this series,
oral antihypertensive agents such as beta-blockers,
angiotensin-converting enzyme inhibitors, labeta-
lol, isordil, calcium channel blockers and rigitine
were also used. A mean blood pressure of 50–60%
of the 24-hour inhospital mean blood pressure
was considered safe in maintaining autoregulation
of blood flow to the brain and other vital organs.
The 24-hour inhospital blood pressure of the pa-
tients scheduled for surgical resection of pheochro-
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mocytoma was required to be < 165/90 mmHg
in this study, and the lowest safe limit of blood
pressure for patients in this study was set at 90
mmHg for SBP, or 55–65 mmHg for MAP. It has
been reported that resection of pheochromocyto-
ma may induce postoperative hypoglycemia due
to increased insulin production.12–15 Since block-
ade of alpha-adrenoceptors may reverse insulin
suppression and blockade of beta-adrenoceptors
reduces muscle glycogenolysis and lipolysis,16,17
labetalol may theoretically induce hypoglycemia
and aggravate hypoglycemia after tumor resec-
tion. This hypothesis was not supported in our pre-
vious study of hysterectomy, which found that
high-dose intravenous labetalol did not induce
hypoglycemia.18 Although for pheochromocytoma,
the output of catecholamines also influences
glucose regulation, the low incidence (18%, 3/16
patients) of postoperative hypoglycemia after
tumor resection in the labetalol group suggested
that this is partly caused by tumor removal and
may not solely be attributed to labetalol. Our data
are also in agreement with those of Orchard et al,
which showed no anesthesia-related mortality.19
In conclusion, this study has clearly demon-
strated that labetalol pretreatment with supple-
mental SNP markedly reduces the hypertensive at-
tack associated with surgical resection of pheo-
chromocytoma. With a loading dose of 1.2 mg/kg,
labetalol pretreatment was associated with mini-
mal hypotensive episodes before tumor resection
and did not lead to any hypotension after tumor
resection. These findings suggest that labetalol
pretreatment (1.2 mg/kg) is ideal for patients un-
dergoing pheochromocytoma resection.
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